SARS‐CoV‐2 variants and vulnerability at the global level

VP Chavda, AB Patel… - Journal of medical …, 2022 - Wiley Online Library
Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity …

[HTML][HTML] Recent review of COVID-19 management: Diagnosis, treatment and vaccination

VP Chavda, S Vuppu, T Mishra, S Kamaraj… - Pharmacological …, 2022 - Springer
The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global …

[HTML][HTML] mRNA-based vaccines and therapeutics for COVID-19 and future pandemics

VP Chavda, S Soni, LK Vora, S Soni, A Khadela… - Vaccines, 2022 - mdpi.com
An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been
sparked by the COVID-19 pandemic. Two years ago, COVID-19's launch propelled mRNA …

[HTML][HTML] Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world

VP Chavda, Q Yao, LK Vora, V Apostolopoulos… - Frontiers in …, 2022 - frontiersin.org
In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health …

[HTML][HTML] Adenoviral vector-based vaccine platform for COVID-19: Current status

VP Chavda, R Bezbaruah, D Valu, B Patel, A Kumar… - Vaccines, 2023 - mdpi.com
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the
21st century, claiming millions of lives and putting a huge burden on the global economy …

Therapeutic monoclonal antibodies for COVID-19 management: an update

VP Chavda, R Prajapati, D Lathigara… - Expert opinion on …, 2022 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

Global impact of delta plus variant and vaccination

VP Chavda, V Apostolopoulos - Expert Review of Vaccines, 2022 - Taylor & Francis
The coronavirus, like all viruses, has mutated numerous times since it first appeared in
China in late 2019. Throughout the pandemic, a number of variants have surfaced, changing …

[HTML][HTML] Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena

VP Chavda, R Bezbaruah, M Athalye, PK Parikh… - Viruses, 2022 - mdpi.com
The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of
human coronavirus (CoV) that is held accountable for the current “coronavirus disease 2019 …

COVID-19 and vaccination: myths vs science

VP Chavda, Y Chen, J Dave, ZS Chen… - Expert Review of …, 2022 - Taylor & Francis
Introduction Several vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have been developed since the inception of the coronavirus disease 2019 …

[HTML][HTML] Conventional and novel diagnostic tools for the diagnosis of emerging SARS-CoV-2 variants

VP Chavda, DD Valu, PK Parikh, N Tiwari, AS Chhipa… - Vaccines, 2023 - mdpi.com
Accurate identification at an early stage of infection is critical for effective care of any
infectious disease. The “coronavirus disease 2019 (COVID-19)” outbreak, caused by the …